Akeso, Inc. (4RY.F)

5.35 -0.40 (-6.96%) At close: 03:29PM CEST

Akeso, Inc.

No. 6, Shennong Road
Torch Development Zone
Zhongshan 528437
China
86 76 0898 73998
https://www.akesobio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2,778

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Yu Xia Ph.D.	Founder, CEO, President & Chairwoman	830.47k	N/A	1967
Dr. Baiyong Li Ph.D.	Co-Founder, Executive VP, CSO & Executive Director	638.51k	N/A	1969
Mr. Zhongmin Wang Ph.D.	Co-Founder, Senior VP & Executive Director	457.75k	N/A	1969
Mr. Yu Xia Ph.D.	Senior VP & Executive Director	495.81k	N/A	1971
Dr. Peng Zhang Ph.D.	Co-Founder & Senior VP	N/A	N/A	N/A
Dr. Xinfeng Zhang	Senior Vice President	N/A	N/A	N/A
Mr. Wenjun Shi	Senior Vice President	N/A	N/A	N/A
Dr. Mingxiu Hu Ph.D.	Senior Vice President	N/A	N/A	N/A
Dr. Charlie Zhang Ph.D.	Senior Vice President	N/A	N/A	N/A
Dr. Jing Min Ph.D.	Senior Vice President	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK105, a PD-1 monoclonal antibody to treat classic Hodgkin's lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals; AstraZeneca Pharmaceuticals; Summit Therapeutics Inc.; and Shenzhen Chipscreen Biosciences Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.

Corporate governance

Akeso, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.